 |
The BioCentury ShowAuthor: BioCentury
Tune in to BioCenturys in-depth conversations with global leaders who are advancing the future of medicine.Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.The BioCentury Show is THE only place where BioCenturys experts join top innovators and global influencers to show how science is being turned into medicine.Don't miss this event, every two weeks, now available as a video webcast or audio podcast. Language: en-us Genres: Business, Life Sciences, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Ep. 116 - Ovid's Jeremy Levin on biotech in the balance
Episode 116
Thursday, 6 August, 2026
Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy Levin has challenged the industry to live up to its ideals. In an interview with BioCentury Washington Editor Steve Usdin, Levin discussed why he believes industry leaders should speak out, and why many remain silent, about critical issues. He described concerns about the strength of the pillars that support the U.S. biotech industry, and why he is optimistic about the future of biotech.View full story: https://www.biocentury.com/article/660408#Biotech #DrugPricing #BiopharmaPolicy #ChinaBiotech #Innovation00:00 - Introduction03:24 - Biotech Under Threat10:38 - CEO Compensation15:39 - Competing with China22:08 - U.S. Policy Prescriptions30:00 - Looking Ahead
